Viyash Scientific credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
436436446451398
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
166166377379356
0.14×0.14×0.58×0.63×0.53×
0.05×0.05×0.49×0.53×0.48×
0.67×0.67×2.76×7.35×33.28×
0.28×0.25×2.33×6.17×29.79×
6.05×6.05×1.57×0.00×−1.23×
12.3%12.3%36.7%38.8%34.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIYASH₹224.55

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹9,809 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt397.9451.3446.4435.8435.8
Net Debt356.1378.8377.2166.1166.1
Total Debt/Equity0.530.630.580.140.14
Net Debt/Equity0.480.530.490.050.05
Total Debt/EBITDA33.287.352.760.670.67
Net Debt/EBITDA29.796.172.330.250.28
Interest Coverage (EBIT/Interest)-1.230.001.576.056.05
Total Debt/Total Capital %34.6938.7636.6912.2712.27
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.